Company Description
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States.
The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.
It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector.
In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections.
Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services.
The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
| Country | United States |
| Founded | 1998 |
| IPO Date | Nov 15, 2006 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 900 |
| CEO | Joseph Papa |
Contact Details
Address: 300 Professional Drive Gaithersburg, Maryland 20879 United States | |
| Phone | 240 631 3200 |
| Website | emergentbiosolutions.com |
Stock Details
| Ticker Symbol | EBS |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001367644 |
| CUSIP Number | 29089Q105 |
| ISIN Number | US29089Q1058 |
| Employer ID | 14-1902018 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph C. Papa Jr. | Chief Executive Officer, President and Director |
| Richard S. Lindahl M.B.A. | Executive Vice President, Chief Financial Officer and Treasurer |
| Coleen Glessner | Chief Quality and Compliance Officer |
| Paul A. Williams | Senior Vice President of Products Business |
| William Hartzel | Senior Vice President of Manufacturing and Bioservices |
| Jessica Perl | Senior Vice President, Corporate Secretary and General Counsel |
| Michelle Pepin | Senior Vice President and Chief Human Resource Officer |
| Stephanie Duatschek | Chief Global Strategy and Franchise Development Officer |
| Simon C. Lowry M.D. | Chief Medical Officer and Head of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2025 | 8-K | Current Report |
| Mar 24, 2025 | EFFECT | Notice of Effectiveness |
| Mar 24, 2025 | 424B3 | Prospectus |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 21, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 21, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 21, 2025 | ARS | Filing |
| Mar 12, 2025 | 144 | Filing |
| Mar 12, 2025 | 144 | Filing |
| Mar 10, 2025 | 8-K | Current Report |